| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2011 | Dec, 2010 |
| Sales | 0 | 0 | 0 | 3,073,100 | 2,748,300 |
| Sales Growth | unch | unch | -100.00% | +11.82% | -1.48% |
| Net Income | -46,060 | -42,130 | -20,820 | 207,800 | 172,300 |
| Net Income Growth | -9.33% | -102.35% | -110.02% | +20.60% | +6,992.00% |
Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cyteir Therapeutics Inc. is a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer. Cyteir Therapeutics Inc. is based in LEXINGTON, Mass.
Fiscal Year End Date: 12/31